Viveve Medical, Inc. (VIVE) Q3 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Vavid Third Quarter 2022 Financial Results in Corporate Update Conference Call. All participants will be in listening mode. If you need assistance, please signal a conference specialist by pressing the star key followed by zero. Please note that this event is recorded. I'll turn the call over to Ms. Jeanne Sundell of Vavid, Senior Director of Corporate Communications. Please go ahead. Thank you, Operator, and welcome, everyone. Before we begin, we would like to remind you that this conference call may contain forward-looking statements regarding future events or the future financial performance of the company. Any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the corporation's cost, timing, progress, and results of its clinical trials, including the initiation, progress of, and results from our pursuit trial, and whether the clinical trial will support the intended uses for treatment of stress urinary incontinence in the United States, fluctuation of global market economic conditions, impact of COVID-19 on clinical development, regulatory review and clearances, manufacturing, system placements and utilization, projections, expectations, plans, beliefs, and prospects. These statements are based on judgments and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are described more fully in the company's annual report on Form 10-K and other filings made with the SEC, which are also available on the company's website. Also, any forward-looking statements represent management's view only as of t...